|Videos|July 21, 2022
How Ruxolitinib Will Change the Future of Vitiligo Treatment
Author(s)Kaitlyn Bader, Associate Editor
Pearl Grimes, MD, FAAD, and director of the Grimes Center of Medical and Aesthetic Dermatology and the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, explains why the FDA approval of ruxolitinib cream 1.5% is monumental in the treatment of vitiligo.
Advertisement
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Priority Review to Zasocitinib for Moderate-to-Severe Plaque Psoriasis
2
FDA Accepts Bezuclastinib NDA for Advanced Systemic Mastocytosis
3
Genetic Study Links Higher BMI to Perceived Facial Aging, but Causality Remains Unproven
4
Defining AD Disease Flares vs Drug Effects: A Comparative Analysis of Phase 3 Systemic Therapy Trials
5